Health ❯ Healthcare ❯ Pharmaceuticals ❯ Cancer Treatment

Bladder Cancer

Macau Approves Anktiva for BCG-Unresponsive Bladder Cancer in First Asia Nod

The move underscores plans to seek more Asia-Pacific approvals.

EU Grants Conditional Approval for ImmunityBio’s Anktiva in BCG‑Unresponsive Bladder Cancer

ImmunityBio Rallies as Anktiva Sales Surge 700% and Registrational Trial Passes 85% Enrollment

FDA Approves Perioperative Keytruda–Padcev for Cisplatin‑Ineligible Muscle‑Invasive Bladder Cancer

FDA Approves J&J’s Inlexzo Bladder Drug-Delivery Device for BCG‑Unresponsive NMIBC